Ten63 Therapeutics, an advanced AI drug-discovery company, has announced that it added strategic investment from new investors Chugai Venture Fund and the Gates Foundation, bringing the Company's total funding to over $45 million.

Ten63 is an advanced AI drug-discovery company that was a Duke and TTIC spin-out, headquartered in the Research Triangle in North Carolina. Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. The company is advancing an internal oncology pipeline while pursuing select, strategic partnerships across multiple indications.